newsfilter
← Latest News
PR Newswire·

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

MARLBOROUGH, Mass., Dec. 21, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound,